About Olio Labs (YC23

Olio Labs utilizes artificial intelligence and machine learning to develop combination therapeutics that account for the complex interactions of proteins in the human body, rather than focusing on single-target treatments. This approach enables the identification of more effective therapies with reduced side effects for challenging diseases by automating the discovery and development process.

```xml <problem> Traditional drug development focuses on single-target treatments, neglecting the complex interactions of proteins within the human body. This approach can lead to less effective therapies and increased side effects, especially for complex diseases. </problem> <solution> Olio Labs is developing combination therapeutics using artificial intelligence and machine learning to account for the intricate network of protein interactions. Their platform, the Combination Design Engine, analyzes thousands of interacting proteins to identify drug combinations that are more effective and have fewer side effects than single-target approaches. By automating the discovery and development process, Olio Labs aims to create better therapies for challenging diseases. The platform designs combination therapies that deliver better outcomes with fewer side effects. </solution> <features> - AI-powered platform analyzes thousands of interacting proteins. - Combination Design Engine identifies synergistic drug combinations. - Focus on developing therapies with improved efficacy and reduced side effects. - Automation of the drug discovery and development process. </features> <target_audience> The primary target audience includes individuals and healthcare providers seeking more effective treatments for complex diseases with fewer side effects. </target_audience> ```

What does Olio Labs (YC23 do?

Where is Olio Labs (YC23 located?

Olio Labs (YC23 is based in Palo Alto, United States.

When was Olio Labs (YC23 founded?

Olio Labs (YC23 was founded in 2023.

How much funding has Olio Labs (YC23 raised?

Olio Labs (YC23 has raised 4200000.

Location

Palo Alto, United States

Founded

2023

Funding

4200000

Employees

6 employees

Major Investors

Y Combinator, Pioneer Fund, ZAKA VC, Unpopular Ventures

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Olio Labs (YC23

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

oliolabs.co 1K+

Crunchbase

Founded 2023 – Palo Alto, United States

Funding

Estimated Funding

$3M+

Major Investors

Y Combinator, Pioneer Fund, ZAKA VC, Unpopular Ventures

Team (5+)

No team information available.

Company Description

Problem

Traditional drug development focuses on single-target treatments, neglecting the complex interactions of proteins within the human body. This approach can lead to less effective therapies and increased side effects, especially for complex diseases.

Solution

Olio Labs is developing combination therapeutics using artificial intelligence and machine learning to account for the intricate network of protein interactions. Their platform, the Combination Design Engine, analyzes thousands of interacting proteins to identify drug combinations that are more effective and have fewer side effects than single-target approaches. By automating the discovery and development process, Olio Labs aims to create better therapies for challenging diseases. The platform designs combination therapies that deliver better outcomes with fewer side effects.

Features

AI-powered platform analyzes thousands of interacting proteins.

Combination Design Engine identifies synergistic drug combinations.

Focus on developing therapies with improved efficacy and reduced side effects.

Automation of the drug discovery and development process.

Target Audience

The primary target audience includes individuals and healthcare providers seeking more effective treatments for complex diseases with fewer side effects.